For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Vyndamax and Attruby represents a genuine advancement . These novel therapies stabilize the transthyretin protein, halting its destructive build-up and reducing the impact of the condi